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Purpose: To analyze two candidate genes, trabecular meshwork inducible glucocorticoid response (MYOC/TIGR) and
human dioxin-inducible cytochrome P450 (CYP1B1), in a Chinese pedigree of primary open-angle glaucoma.
Methods: In a three-generation family containing 14 members, four of them were patients with primary open-angle
glaucoma, one was a glaucoma suspect, and the rest were asymptomatic. All members of the family underwent complete
ophthalmologic examinations. Exons of MYOC and CYP1B1 were amplified by polymerase chain reaction, sequenced,
and compared with a reference database.
Results: Elevated intraocular pressure and impaired visual field were found in all patients. One MYOC heterozygous
mutation G367R, in exon 3 was identified in four patients and the suspect, but not in the rest of the family members.
Meanwhile, four single nucleotide polymorphisms in MYOC and CYP1B1 genes were found.
Conclusions: Although the G367R mutation of MYOC, which causes primary open-angle glaucoma in the form of
autosomal dominant inheritance, has been reported in some other ethnicities, it was found in Chinese pedigree for the first
time.
Glaucoma is one of the leading causes of blindness in the
world and is characterized by optic disc cupping and visual
field defects [1,2]. Primary open-angle glaucoma (POAG) is
the most common form of glaucoma [3]. There are two forms
of POAG: juvenile onset and adult onset. Usually, juvenile
open  angle  glaucoma  (JOAG)  may  manifest  clinically
between  the  ages  of  3  and  30  [4,5],  while  adult  POAG
manifests clinically after the age of 40 [6,7]. Although the
exact mechanisms of POAG remain unclear, the accumulating
evidences suggest that the genetic basis plays an important
role in its pathogenesis. Four genes, trabecular meshwork
inducible  glucocorticoid  response  (MYOC/TIGR),  human
dioxin-inducible  cytochrome  P450  (CYP1B1),  optineurin
(OPTN), and WD repeat domain 36 (WDR36), have been
identified as glaucoma-causing genes [8], with MYOC being
the first identified POAG gene [9]. To date, more than 70
mutations  have  been  detected  in  MYOC  worldwide  [10].
About 90% of the mutations were located in exon 3 where the
olfactomedin-like  domain  is  located  [11].  Recently,
CYP1B1 has been shown to be related to POAG, especially
JOAG [12-14]. Both MYOC and CYP1B1 consist of three
exons, but in CYP1B1, only exon 2 and 3 encode the protein.
In  this  study,  alterations  in  MYOC  (three  exons)  and
CYP1B1 (exon 2 and 3) were analyzed, and a known mutation
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(c.1099  G>A,  G367R)  in  exon  3  of  MYOC,  which  was
segregated with the disorder within the family and appeared
to be the disease-causing gene, was found. It is for the first
time, to the best of our knowledge, that G367R mutation was
found in Chinese.
METHODS
Clinical  examination: This  three-generation  pedigree  with
POAG  (Figure  1)  was  recruited  from  the  out-patient
department  of  Ophthalmology  at  West  China  Hospital
(Sichuan University, Chengdu, P. R. China). All members of
the  family  underwent  the  complete  ophthalmologic
examinations including slit-lamp biomicroscopy, gonioscopic
examination,  fundoscopic  examination,  IOP  measurement
(Canon TX-F Non-contact tonometer; Canon Inc., Tokyo,
Japan), and visual field test (Octopus 900; HAAG-STREIT
International, Berne, Swiss). Diagnostic criteria for POAG
included  open  anterior  chamber  angle,  elevated  IOP
(≥22  mmHg),  glaucomatous  visual  field  defects  and
characteristic optic disc damage.
The study was approved by the medical ethics committee
of the West China Hospital of Sichuan University. This study
follows  the  principles  of  the  Declaration  of  Helsinki.  All
subjects were clinically evaluated by glaucoma specialists.
Detection of MYOC and CYP1B1 mutations: Genomic DNA
was  extracted  from  0.2  ml  peripheral  blood  sample  with
Qiamp Blood Kit (Qiagen, Hilden, Germany) according to the
manufacturer’s instruction.
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1431Intronic primers flanking the exons were designed (Table
1) based on gene sequences of MYOC (GenBank AF001620)
and  CYP1B1  (GenBank  U56438)  and  synthesized  by
Invitrogen (Carlsbad, CA). PCR amplification was performed
in a MyCycler thermocycler (Bio-Rad, Hercules, CA). The
30 μl PCR reaction mixtures included 30 ng DNA, 1× PCR
buffer, 2.5 mM MgCl2, 0.3 mM of each of dNTPs, 1.5 U Pfu
DNA polymerase, and 1.0 μM each of the forward and reverse
primers. All reagents used in this procedure were purchased
from TaKaRa (Dalian, China). The reactions were incubated
at 95 °C for 4 min followed by 35 cycles at 95 °C for 30 s,
58 °C for 30s, and 72 °C for appropriate time (the second exon
of  MYOC  for  30s  and  the  rest  for  90s),  and  then  a  final
extension at 72 °C for 5 to 10 min.
PCR products were directly sequenced by an ABI 377XL
automated DNA sequencer (Applied Biosystems, Foster City,
CA).  Sequence  data  were  compared  pair-wise  with  the
published MYOC and CYP1B1 sequences.
RESULTS
The proband and other patients (Table 2): The proband (II-3)
was diagnosed with POAG (both eyes) at the age of 46, with
elevated IOPs (26.7 mmHg in the right eye and 23.1 mmHg
in the left eye), open anterior chamber angle, enlarged cup-
disc ratio of 0.5/0.6(OD/OS) and characteristic glaucomatous
visual field defects (Figure 2). Other ocular abnormalities or
systemic disorders were not found.
The proband’s mother (I-2) was diagnosed with POAG
at the age of 38, and trabeculectomy was performed for both
eyes twenty-one years ago. During this examination, a cup/
disc ratio of 0.95/1.0 (OD/OS), IOPs at 16.7/19.1 mmHg (OD/
OS),  and  late-stage  glaucomatous  visual  field  loss  were
noticed (Figure 2). II-1 was a JOAG patient, and bilateral
trabeculectomies were performed at the age of 34, when his
IOPs were as high as 50~60 mmHg (OU). Patient II- 6 's onset
of the glaucoma was at the age of 20, much earlier than other
family members. Her maximal IOPs measured 50 mmHg in
the right eye and 65 mmHg in the left eye. She underwent
trabeculectomy  in  both  eyes.  The  cup-disc  ratio  of  both
II-1and II-6 was 0.9/0.95 (OD/OS). Patient III- 1, 25 years old,
Figure 1. Pedigree for the Chinese POAG family. The proband was
II-3.
was  a  glaucoma  suspect,  because  he  had  a  strong  family
history of glaucoma and his IOP measured 27.8/21.5 mmHg
(OD/OS), despite no glaucomatous visual field defects and
characteristic optic disc damage.
Asymptomatic family members: The proband’s father (I-1)
didn’t have ocular diseases except senile cataract. No ocular
Figure 2. Visual fields of patients. Visual field of I-2 (A, B), II-1
(C, D), II-3 (E, F), and II-6 (G, H).
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1432abnormalities were found in the rest of the family numbers.
Their visual acuity or corrected visual acuity was measured
≥20/20.
MYOC—Sequence  analysis  of  MYOC  revealed  a
heterozygous mutation, c.1099G>A (G367R), in exon 3 in all
patients  and  the  suspected  one  but  not  in  any  of  the
asymptomatic members of the family. The G367R MYOC
mutation was cosegregated with the disorder within the family
(Figure 3). One single nucleotide polymorphism (SNP, g.
23096344C>T) in exon 2 of MYOC was identified.
CYP1B1—No  mutation  was  found.  Three  CYP1B1
SNPs  (g.17120037A>G,  g.17120090C>G,  and  g.
17120026T>C) were identified in exon 3.
DISCUSSION
MYOC  was  the  first  identified  POAG  gene  [9].  Previous
studies showed that MYOC mutations exist in nearly 3% of
adult onset POAG patients and a greater proportion of JOAG
patients [15,16]. In this study, a G to A transition at the first
base of codon 367 (in exon 3 of MYOC), which resulted in a
glycine to arginine amino acid substitution, was identified,
suggesting that MYOC is the glaucoma-causing gene in this
family. This mutation has been previously reported in several
other ethnic groups: Japanese, Indian, Irish, Swiss, French-
Canadian, Scottish, and German [17-25], however, to the best
of our knowledge, this mutation was found in Chinese for the
first time.
Based on the literature reviewed, the phenotype of POAG
associated with the G367R mutation was summarized in Table
3: 1) there were no obvious differences between gender; 2) all
carriers had open anterior chamber angle; 3) all 6 pedigrees
were  in  autosomal  dominant  fashion;  4)  the  patients  had
relatively high IOP and relatively early onset age; and 6)
medical  control  of  IOP  were  not  satisfied  in  most  of  the
patients,  and  surgeries  were  usually  needed.  The  Chinese
pedigree with G367R mutation reported in this paper was in
general coincidence with the characteristics mentioned.
The phenotypic variations observed here and in previous
studies suggest that, in addition to G367R substitution, some
as  yet  unidentified  factors  (such  as  the  genetic  and/or
environmental)  are  responsible  for  the  disease  phenotype.
Furthermore,  POAG  is  well  known  to  be  genetically
heterogeneous and several loci have been identified except
MYOC.  The  variations  in  these  loci  may  contribute  to
phenotypic  variations.  Recently,  another  gene  CYP1B1,
indeed, has been suggested to modify the glaucoma phenotype
Figure  3.  MYOC  mutation  in  the  POAG  family.  A:  Normal
individuals with homozygous G (arrow). B: The double peak of
guanine (black line) and adenine (green line; B, arrow) represents a
heterozygous mutation at the codon of 367th amino acid residue
(Gly367Arg).
TABLE 1. PRIMERS USED IN PCR FOR AMPLIFICATION OF MYOC AND CYP1B1.
Exons Primer sequence (forward/reverse) Product size (bp)
MYOC 1 PF 5′-CCAAACAGACTTCTGGAAGG-3′ 904
MYOC 1 PR 5′-TAGCAGGTCACTACGAGCC-3′  
MYOC 2 PF 5′-TGTCATCCTCAACATAGTCA-3′ 351
MYOC 2 PR 5′-TTCTGTTCCTCTTCTCCTC-3′  
MYOC 3 PF 5′-CCAGGGCTGTCACATCTACT-3′ 933
MYOC 3 PR 5′-CATCTCCTTCTGCCATTGC-3′  
CYP1B1 2 PF 5′-CATTTCTCCAGAGAGTCAGC-3′ 1260
CYP1B1 2 PR 5′-GCTTGCAAACTCAGCATATTC-3′  
CYP1B1 3 PF 5′-ACCCAATGGAAAAGTCAGCC-3′ 927
CYP1B1 3 PR 5′-GCTTGCCTCTTGCTTCTTATT-3′  
TABLE 2. PATIENT DATA FROM THIS POAG PEDIGREE
Patient Age at study
(years)
Diagnosis age
(years)
Operation age
(years)
Maximal IOP
(mmHg)
C/D ratio Visual field
damage
I-2 68 38 41 >50 (ou) 0.95/1.0 Severe
II-1 48 30 34 50~60 (ou) 0.9/0.95 Moderate
II-3 46 46 — 28.9 (od), 28.1 (os) 0.5/0.6 Moderate
II-6 42 20 24 50 (od), 65 (os) 0.9/0.95 Severe
III-1 25 25 — 24.4 (od), 23.6 (os) 0.2 Normal
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genes  may  interact  via  a  common  pathway  [26,27].  We
continued to screen CYP1B1 gene, but no mutations, except
three SNPs, were detected.
It is known that patients with missense mutations such as
G367R are likely to present the normal and mutant mRNA in
equal amounts, and then the mRNA is translated into an equal
ratio of mutant and normal proteins. Myocilin was thought to
be  a  secreted  protein  [28],  but  mutant  Myocilin  formed
insoluble  aggregates  that  could  not  be  secreted  out  from
human trabecular meshwork (HTM) cells and accumulated
intracellularly, then damaged the function of HTM cells and
resulted in an increase of aqueous humor outflow resistance
[29-31]. So far, the secretion of G367R mutation myocilin
protein has been studied in vitro and in vivo, which revealed
the same mechanism above [32].
In conclusion, the G367R mutation of MYOC in this
pedigree appears to be the cause of the disease in this family.
This is the first time that this mutation was found in Chinese
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